Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

504.10 -2.64 (-0.52%)

Delayed Quote Updated: 3:27 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

69 70 Next >

Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? ↗

October 01, 2026

Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward...

Via The Motley Fool

Topics Intellectual Property

2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. ↗

September 29, 2026

This biotech player is firing on all cylinders.

Via The Motley Fool

Topics Intellectual Property

2 Healthcare Stocks to Target This Week and 1 We Avoid

September 28, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry...

Via StockStory

2 Healthcare Stocks That Just Delivered Great News for Investors ↗

September 26, 2026

And there could be more positive developments ahead.

Via The Motley Fool

CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 24, 2026

One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles.

Via The Motley Fool

3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026 ↗

September 20, 2026

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

Via The Motley Fool

Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback? ↗

September 18, 2026

This company has had plenty of setbacks in recent years, but it generally bounces back.

Via The Motley Fool

2 Reasons to Like VRTX (and 1 Not So Much)

September 18, 2026

Vertex Pharmaceuticals has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13....

Via StockStory

Topics Stocks

Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? ↗

September 17, 2026

With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.

Via The Motley Fool

My Top 5 Favorite Stocks for an Uncertain Market ↗

September 16, 2026

These players offer a certain level of stability in any market environment.

Via The Motley Fool

Topics Artificial Intelligence Economy Intellectual Property

Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead ↗

September 14, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and cell therapies among the company’s...

Via MarketBeat

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 14, 2026

Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality.

Via The Motley Fool

September 14, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Via StockStory

Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis ↗

September 12, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a...

Via MarketBeat

Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference ↗

September 12, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent Crinetics acquisition, planned renal...

Via MarketBeat

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

September 09, 2026

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD...

Via StockStory

Topics Artificial Intelligence

Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock ↗

September 08, 2026

The company has tremendous prospects.

Via The Motley Fool

Topics Intellectual Property

Why CRISPR Therapeutics Stock Rocked the Market Last Month ↗

September 08, 2026

The company had fallen out of investor favor; its recovery was impressive.

Via The Motley Fool

Where Will CRISPR Therapeutics Stock Be in 5 Years? ↗

September 08, 2026

CRISPR's expanding pipeline could unlock significantly more value by 2031.

Via The Motley Fool

3 Market-Beating Stocks for Long-Term Investors

September 08, 2026

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y...

Via StockStory

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? ↗

September 04, 2026

They could both outperform the market over the medium term, but one appears to have a clear edge.

Via The Motley Fool

Topics Intellectual Property

Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today ↗

September 04, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.61% on an annualized basis producing an average annual return of 14.84%. Currently, Vertex Pharmaceuticals...

Via Benzinga

3 Stocks Whose Competitive Walls Tower Over Nvidia's ↗

September 03, 2026

A solid moat favors revenue growth, and that's good news for investors.

Via The Motley Fool

Topics Artificial Intelligence

2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026 ↗

September 02, 2026

We'll know a little more about the company's prospects by the end of the year.

Via The Motley Fool

1 S&P 500 Stock with Exciting Potential and 2 We Ignore

August 31, 2026

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

Via StockStory

Topics Stocks

If You Invested $100 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗

August 27, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.32% on an annualized basis producing an average annual return of 14.56%. Currently, Vertex Pharmaceuticals...

Via Benzinga

2 Large-Cap Stocks to Research Further and 1 We Question

August 26, 2026

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m...

Via StockStory

Inflation Is Rising Again. History Says These 2 Stocks Are Among the Smartest Places to Hide ↗

August 24, 2026

Inflation affects corporations differently. These two have the tools to navigate the challenge better than most.

Via The Motley Fool

Topics Economy Intellectual Property

Vertex Pharmaceuticals: A Biotech Cash Cow With Pipeline Upside? ↗

August 21, 2026

Vertex dominates cystic fibrosis and has a debt-free balance sheet, but can its pipeline restore faster growth? See why our analysts gave the stock a strong 7.3 out of 10.

Via The Motley Fool

CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money? ↗

August 21, 2026

This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500.

Via The Motley Fool

Topics ETFs Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Vertex Pharmaceuticals (NQ:VRTX)

Headline News about Vertex Pharmaceuticals

Resources